Abstract
Dearth of Reliable Conventional Therapies for Serious/Long-term Illnesses Boosts Markets for Therapeutic mAbs
The shortage of reliable conventional therapies for critical illnesses is propelling demand for monoclonal antibodies (mAbs), which work closely with the bodys natural biomedical systems. Estimates indicate that more than two-thirds of therapeutic mAbs are used for transplant rejection, cancer, and autoimmune and infectious diseases. Sales in the billion dollar range and growing investments in mAb development, underline the clinical credibility of the therapy for serious long-term conditions such as non-hodgkins disease, psoriasis, allergic asthma, rheumatoid arthritis, and Crohns disease. To increase awareness on the benefits of mAbs, it is necessary to allot a large budget, while also implementing well designed communication strategies.
This Frost & Sullivan research service provides an overview of and an outlook for the therapeutic mAb market in United States, detailing revenue forecasts by region and segments as well as providing market share analyses. It looks into the major market sectors for therapeutic mAbs such as oncology, auto-immune and inflammatory disorders, cardiovascular disorders, organ transplants, and infectious diseases. This information is valuable to both large and small market participants seeking to position themselves for maximum return on investment.
High Specificity mAbs Provides Attractive Therapeutic Solutions
mAbs, particularly the human type, have a high binding capacity and specificity that make them suitable for targeted attacks on tumor cells, infectious agents, infected cells, and other human biomaterials related to diseases. It can target any antigen or molecule in the human body. "Unlike the traditional drugs, mAbs can prevent the disease-causing target cells from spreading without damaging the healthy cells in the adjacent tissues," points out the analyst of the research. "They attack specific antigens (within cells, tissues and organs) and do not have off-target effects, thus eliminating side-effects. "Due to this characteristic, mAbs offer high commercial viability and are successfully used in clinical applications.
Broadening Indication Range of Therapeutic mAbs Attract New Patient Groups
With the initial approval being rather cautious, mAbs are often restricted to a single indication comprising smaller patient population. However, companies are extending their indications domain within the same disease area, eventually covering different sets of patients. "Enterprises are increasingly conducting research on pipeline products to develop successful multi-target indications, in almost the same amount of time earlier consumed to develop a single product indication," notes the analyst.
To enhance this product development, big pharmaceutical companies are developing alliances with smaller biotech companies in mAb research for specific products and technologies. These alliances can balance the small biotech companies capabilities in mAb generation and optimization, along with their process technology and early clinical skills, with the superior drug development capabilities and domestic and global reach of the big pharmaceutical companies.
View Cart
